LV PACKAGING AND PRODUCER CELL LINES

LentiVEX™ packaging cell lines

OXGENE has successfully developed a suspension-mode, stable lentiviral packaging cell line platform using a proprietary Tet-inducible system. This demonstrates high titre lentiviral production with single plasmid transfection in both shake flask and bioreactor.

Our packaging cell lines, containing inducible VSV-G, Gag-Pol and Rev, have been developed with full traceability from a GMP banked cell line, and provide a simple, flexible platform from which to test multiple transgenes, or variants of a transgene, for further development.

We use a fully defined, serum/animal component free process to generate both our packaging and producer GMP-compliant HEK293 cell lines, which do not contain the SV40 Large-T antigen and remain stable in the absence of antibiotic selection, minimising the regulatory risks in transitioning to clinical use.

View our most recent poster here.

LentiVEX™ producer cell lines

Our packaging cell lines also form the basis of our animal component free custom producer cell lines, derived from a GMP banked master cell line using our automated platform to screen thousands of single cell clones. These permit transfection-free, large-scale production of lentiviral vectors for cell or gene therapies. This reduces the overall cost of goods and process complexity involved in clinical-scale viral vector production, while improving scalability and system reproducibility.

A further advantage of producer cell lines is the added potential for process development to improve viral titres once we've stably integrated your gene of interest, free from the process limitations imposed by transfection. Overall, lentiviral producer cell lines allow the consistent production of large quantities of lentiviral vector at lower cost.

OXGENE’s producer cell lines use our proprietary LentiVEX™ genetic system, which is optimised for translation efficiency, has Tet inducible VSV-G and Gag-Pol expression, and low homology between expression cassettes for an improved safety profile.

We use a fully defined, serum/animal component free process to generate both our packaging and producer GMP-compliant HEK293 cell lines. Cell lines do not contain the SV40 Large-T antigen and remain stable in the absence of antibiotic selection, minimising the regulatory risks in transitioning to clinical use.

View our most recent poster here.